Ammar Al Rubaiay
Podiatrist · New Hyde Park, NYNPI 1831623511
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 22.2%. 2025 is the largest year on record at $10,967, 9.5 times the $1,151 reported in 2020. Among podiatrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $90.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Treace Medical Concepts, Inc.$6K
- Kerecis Limited$5K
- Stryker$4K
- Smith+Nephew$3K
- Gotham Surgical Solutions & Devices, Inc.$2K
- Paragon 28, Inc.$541
- plus $5K from 29 others
What the payments were for
- Consulting fees$2,93612%
- Speaking & faculty fees$2,94412%
- Travel & lodging$2,46610%
- Food & beverage$13,84756%
- Education$2,65011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Treace Medical Concepts, Inc. | 25 | $5,503 |
| Kerecis Limited | 10 | $4,939 |
| Stryker | 44 | $4,255 |
| Smith+Nephew | 73 | $2,604 |
| Gotham Surgical Solutions & Devices, Inc. | 3 | $2,425 |
| Paragon 28, Inc. | 7 | $541 |
| Polynovo North America LLC | 5 | $478 |
| Inari Medical, Inc. | 2 | $378 |
| Tactile Systems Technology Inc | 13 | $302 |
| Paratek Pharmaceuticals, Inc. | 11 | $291 |
| KCI USA, Inc. | 8 | $286 |
| Zimmer Biomet | 5 | $276 |
| Nevro Corp. | 5 | $240 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 10 | $220 |
| Osteomed LLC | 3 | $215 |
| Musculoskeletal Transplant Foundation Inc. | 6 | $171 |
| Biocomposites Inc | 5 | $163 |
| Integra Lifesciences Corporation | 3 | $160 |
| Organogenesis Inc. | 1 | $150 |
| Solventum Corporation | 5 | $143 |
| Acera Surgical, Inc. | 2 | $140 |
| Averitas Pharma Inc. | 2 | $139 |
| Nalu Medical, Inc. | 1 | $122 |
| Bioventus LLC | 3 | $114 |
| Baxter Healthcare | 1 | $108 |
| Convatec Inc. | 6 | $105 |
| Polaris Technology Solutions LLC | 3 | $92 |
| Vertex | 3 | $72 |
| Orthofix Medical, Inc. | 2 | $64 |
| Advanced Oxygen Therapy Inc. | 2 | $42 |
| Misonix Inc | 1 | $25 |
| Sandoz | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $21 |
| Next Science LLC | 1 | $18 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$14,399
- LAPIPLASTY SYSTEM 1$4,220
- Kerecis GraftGuide$3,600
- Kerecis Omega3 Marigen$2,860
- Kerecis Omega3 SurgiClose$2,503
- Kerecis Omega3 GraftGuide$980
- FLEXBAND$879
- HOFFMANN$778
- PROstep$555
- CITREFIX$549
- 7 X 23MM CITRELOCK IMPLANT$533
- Stravix$531
- FLOWTRIEVER CATHETER, S$378
- CT THROMBECTOMY SYSTEM KIT$378
- Novosorb BTM$362
- ALLOWRAP$360
- INFINITY$302
- PERCUPLASTY TRAY$246
- COLLAGENASE SANTYL$234
- MONKEY RINGS$223
How this compares
$24,843 in reported general payments places this provider in the 95th percentile of 862 podiatrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 11 | $3,743 |
| CiclopiroxCiclopirox Olamine | 40 | $1,073 |
| Ciclopirox | 25 | $721 |
| Mupirocin | 74 | $502 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $319 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $225 |
| Ammonium Lactate | 11 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $2,604 | $3,74311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 862 podiatrist providers in New York.
Other podiatrist in New Hyde Park
- Christopher BromleyPoughkeepsie$152K
- Scott GawlikBrooklyn$77K
- Waldemar MajdanskiAstoria$71K
- Michael HutzelSeaford$64K
- Donald RubinCorning$53K
- Steven NormanMiddle Village$42K
- Elvis DanneNew York$35K
- Adam CirlincioneGlen Cove$31K
- Jude ViolanteNiagara Falls$30K
- Jennifer SweetBinghamton$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.